These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 8872326)

  • 1. Technical approach for the study of the genetic evolution of breast cancer from paraffin-embedded tissue sections.
    Chen T; Dhingra K; Sahin A; Sneige N; Hortobagyi G; Aldaz CM
    Breast Cancer Res Treat; 1996; 39(2):177-85. PubMed ID: 8872326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis.
    Murphy DS; Hoare SF; Going JJ; Mallon EE; George WD; Kaye SB; Brown R; Black DM; Keith WN
    J Natl Cancer Inst; 1995 Nov; 87(22):1694-704. PubMed ID: 7473818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutation of the TP53 gene and allelic imbalance at chromosome 17p13 in ductal carcinoma in situ.
    Munn KE; Walker RA; Menasce L; Varley JM
    Br J Cancer; 1996 Nov; 74(10):1578-85. PubMed ID: 8932338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral heterogeneity in breast carcinoma revealed by laser-microdissection and comparative genomic hybridization.
    Aubele M; Mattis A; Zitzelsberger H; Walch A; Kremer M; Hutzler P; Höfler H; Werner M
    Cancer Genet Cytogenet; 1999 Apr; 110(2):94-102. PubMed ID: 10214356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative allelotype of in situ and invasive human breast cancer: high frequency of microsatellite instability in lobular breast carcinomas.
    Aldaz CM; Chen T; Sahin A; Cunningham J; Bondy M
    Cancer Res; 1995 Sep; 55(18):3976-81. PubMed ID: 7664266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of heterozygosity and microsatellite instability in ductal carcinoma in situ of the breast.
    Ando Y; Iwase H; Ichihara S; Toyoshima S; Nakamura T; Yamashita H; Toyama T; Omoto Y; Karamatsu S; Mitsuyama S; Fujii Y; Kobayashi S
    Cancer Lett; 2000 Aug; 156(2):207-14. PubMed ID: 10880771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast.
    Lininger RA; Zhuang Z; Man Y; Park WS; Emmert-Buck M; Tavassoli FA
    Mod Pathol; 1999 Dec; 12(12):1083-9. PubMed ID: 10619258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of chromosome aneuploidy in tissue sections of preinvasive breast carcinomas using interphase cytogenetics.
    Visscher DW; Wallis TL; Crissman JD
    Cancer; 1996 Jan; 77(2):315-20. PubMed ID: 8625240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 mutations and expression in breast carcinoma in situ.
    Lukas J; Niu N; Press MF
    Am J Pathol; 2000 Jan; 156(1):183-91. PubMed ID: 10623666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of p53 mutations in cells taken from paraffin-embedded tissue sections of ductal carcinoma in situ and atypical ductal hyperplasia of the breast.
    Keohavong P; Gao WM; Mady HH; Kanbour-Shakir A; Melhem MF
    Cancer Lett; 2004 Aug; 212(1):121-30. PubMed ID: 15246568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 mutations and histological type of invasive breast carcinoma.
    Marchetti A; Buttitta F; Pellegrini S; Campani D; Diella F; Cecchetti D; Callahan R; Bistocchi M
    Cancer Res; 1993 Oct; 53(19):4665-9. PubMed ID: 8402644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias.
    Done SJ; Arneson NC; Ozçelik H; Redston M; Andrulis IL
    Cancer Res; 1998 Feb; 58(4):785-9. PubMed ID: 9485035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identical allelic loss on chromosome 11q13 in microdissected in situ and invasive human breast cancer.
    Zhuang Z; Merino MJ; Chuaqui R; Liotta LA; Emmert-Buck MR
    Cancer Res; 1995 Feb; 55(3):467-71. PubMed ID: 7834608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allelic loss on a chromosome 17 in ductal carcinoma in situ of the breast.
    Radford DM; Fair K; Thompson AM; Ritter JH; Holt M; Steinbrueck T; Wallace M; Wells SA; Donis-Keller HR
    Cancer Res; 1993 Jul; 53(13):2947-9. PubMed ID: 8391383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular abnormalities associated with secretory carcinomas of the breast.
    Maitra A; Tavassoli FA; Albores-Saavedra J; Behrens C; Wistuba II; Bryant D; Weinberg AG; Rogers BB; Saboorian MH; Gazdar AF
    Hum Pathol; 1999 Dec; 30(12):1435-40. PubMed ID: 10667421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications.
    Gao X; Porter AT; Honn KV
    Adv Exp Med Biol; 1997; 407():41-53. PubMed ID: 9321930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular and immunohistochemical analysis of p53 mutations in scrapings and tissue from preinvasive and invasive breast cancer.
    Lisboa BW; Vogtländer S; Gilster T; Riethdorf L; Milde-Langosch K; Löning T
    Virchows Arch; 1997 Dec; 431(6):375-81. PubMed ID: 9428925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High frequency of chromosome 9p allelic loss and CDKN2 tumor suppressor gene alterations in squamous cell carcinoma of the bladder.
    Gonzalez-Zulueta M; Shibata A; Ohneseit PF; Spruck CH; Busch C; Shamaa M; El-Baz M; Nichols PW; Gonzalgo ML; Elbaz M [corrected to El-Baz M]
    J Natl Cancer Inst; 1995 Sep; 87(18):1383-93. PubMed ID: 7658499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data.
    O'Malley FP; Vnencak-Jones CL; Dupont WD; Parl F; Manning S; Page DL
    Lab Invest; 1994 Jul; 71(1):67-72. PubMed ID: 8041120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Microsatellite alterations on human chromosome 11 in in situ and invasive breast cancer: a microdissection microsatellite analysis and correlation with p53, ER (estrogen receptor), and PR (progesterone receptor) protein immunoreactivity.
    Shen KL; Yang LS; Hsieh HF; Chen CJ; Yu JC; Tsai NM; Harn HJ
    J Surg Oncol; 2000 Jun; 74(2):100-7. PubMed ID: 10914818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.